Form 4: Director Robert B. Carter Increases Stake in Quest Diagnostics

Quest Diagnostics Director Robert B. Carter acquired 7 shares of common stock through a dividend reinvestment plan.

Summary

• Director Robert B. Carter acquired 7 shares of Quest Diagnostics (DGX) common stock.
• The transaction occurred on April 20, 2026, at a price of $194.699 per share.
• The acquisition was executed via a dividend reinvestment plan.
• Following this transaction, the director's total beneficial ownership stands at 2,711 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding standard dividend reinvestment.

Positives

• Director demonstrates continued commitment to the company through the acquisition of additional shares.
• The transaction reflects participation in a dividend reinvestment plan, signaling confidence in the company's dividend policy.

Negatives

• The volume of shares acquired is nominal (7 shares) and does not represent a significant change in equity position.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider transactions via dividend reinvestment plans are standard corporate governance activities and generally do not indicate a shift in strategic direction or material non-public information.

Comparison to Industry Standards

• The transaction is consistent with standard director equity participation practices observed in large-cap healthcare companies like LabCorp or HCA Healthcare.

Stakeholder Impact

• Minimal impact on shareholders as the transaction size is negligible.

Key Dates

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Dividend Reinvestment, Director Ownership